CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 200678Orig1s000

CHEMISTRY REVIEW(S)

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

NDA 200-678

kombiglyzeTM XR (saxagliptin and metformin HCl extended-release) Tablets

Summary of the Basis for the Recommended Action from Chemistry, Manufacturing, and Controls

Applicant:	Bristol-Myers Squibb Co. P.O. Box 4000,
Background	Princeton, NJ 08543-4000 This NDA is submitted as a 505(b)(1) application. The drug product is a new Fixed Dose Combination. The reference drugs are: Onglyza® (saxagliptin) Tablets (NDA 22-350), Glycophage (metformin HCl) tablets (NDA 20-357) and Glycophage XR (metformin HCl) Tablets (NDA 21-202).
Indication:	The drug product is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both saxagliptin and metformin is appropriate.
Presentation	The proposed drug product will be packaged in high density polyethylene (HDPE) bottles with a two-piece, child-resistant, continuous-thread closure having an aluminum-foil induction seal (inner seal). Larger bottles (e.g., pharmacy or institutional packages) have a one piece continuous-thread closure with an

packages) have a one piece continuous-thread closure with an aluminum-foil induction seal (inner seal). The bottles contain activated carbon/silica gel desiccant packet(s). Physician samples are packaged in ^{(b) (4)} blister.

Establishments Evaluation Report (EER) Status: Acceptable

Consults: EA -

Statistics – Methods Validation – Biopharm– Microbiology – Pharm Toxicology – Acceptable N/A Not recommended Acceptable Acceptable N/A

Original Submission:

DOCKE

Δ

RM

December 30, 2009

Find authenticated court documents without watermarks at docketalarm.com.


Re-submissions: Post-Approval CMC Agreements:

N/ANone at this time.

Drug Substances: Saxagliptin

All information regarding the physicochemical properties, impurities, method of synthesis and purification, process controls, control of raw materials, container closure system and stability of saxagliptin are provided in NDA 22-350 for Onglyza® (saxagliptin) Tablets (from the same applicant as this NDA). The drug substance saxagliptin will be manufactured at the BMS facility in Sword, Ireland. The retest period for saxagliptin is ^{(b) (4)} when stored at USP controlled cold temperature i.e. between 2° and 8°C (36° and 46°F); excursions permitted between 0° and 15°C (32° and 59°F).


Structural formula, chemical name, molecular weight and molecular formula Saxagliptin monohydrate



Chemical Name: (1*S*,3*S*,5*S*)-2-[(2*S*)-2-Amino-2-(3 hydroxytricyclo [3.3.1.1_{3,7}]dec-1yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, monohydrate. Molecular Weight: 333.43 (315.41 anhydrous) g/mol Chemical Formula: C18H25N3O2•H2O

Metformin HCl

All information regarding the physicochemical properties, impurities, method of synthesis and purification, process controls, control of raw materials, container closure system and stability of metformin HCl are provided in the Drug Master Files (DMFs) ^{(b)(4)} both held by ^{(b)(4)} The drug substance is supplied as metformin HCl both held by ^{(b)(4)}. Both of these DMFs were reviewed and found adequate. The retest period for metformin hydrochloride is ^{(b)(4)} when stored in the ^{(b)(4)} described in DMF at long term ICH room temperature conditions. **Structural formula, chemical name, molecular weight and molecular formula**



Chemical name: 1,1- Dimethylbiguanide hydrochloride Molecular Weight: 165.6 g/mol Molecular Formula: C4H12ClN5

Conclusion: The Drug Substances are adequate.

Drug Product:

The proposed drug product is a fixed dose combination of saxagliptin and metformin HCl. The proposed strengths are: saxagliptin 5 mg/metformin HCl 500 mg, saxagliptin 5 mg/metformin HCl 1000 mg, saxagliptin 2.5 mg/metformin HCl 1000 mg.

The application contains a Quality by Design (QbD) approach used during development of the drug product. This approach was utilized for the The QbD implementation approach was similar to the QbD approach used in the approved product ONGLYZA. ONGLYZA was developed following the QbD paradigm and was a part of FDA's CMC Pilot Program. The provided stability data support a shelf life of **15 months** for the blisters and **21 months** for the bottles, when stored at 20° to 25°C (68°-77°F); excursions permitted between 15 and 30°C (59 and 86°F) (see USP Controlled Room Temperature).

Conclusion: The Drug Product is adequate.

DOCKF


Find authenticated court documents without watermarks at docketalarm.com.

(b) (4)

Overall Conclusion: From the CMC point of view, the application is recommended for APPROVAL.

Ali Al-Hakim, Ph.D. Branch Chief, Division III ONDQA/CDRR/FDA

Container label for the 5 mg/1000 mg presentation



(b) (4)

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.